 |
 |
 |
 |
 |
 |
 |
 |
Nelfinavir (Viracept)
Overview
- A Clinical Overview of Nelfinavir (Viracept) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Nelfinavir (Viracept) (PDF) (August 2007)
From Pfizer, Inc. - Drug Interactions: Nelfinavir (August 2004)
From Project Inform
News
- Viracept (Nelfinavir Mesylate) 250 mg, 625 mg Tablets, and Powder for Oral Suspension: Important Information for Prescribers (PDF) (May 6, 2008)
From Pfizer, Inc. - Heavy Restrictions on Nelfinavir Use Recommended for Pediatric Patients, Pregnant Women in United States (September 10, 2007)
From U.S. Food and Drug Administration - European Union Suspends HIV Med Viracept Due to Toxic Contamination (August 7, 2007)
The European Commission said it had suspended Roche's license to market its HIV drug Viracept in the European Union. The drug was withdrawn from the market in June after Roche said some batches were contaminated with ethyl mesilate, which can cause tumors. The commission said the latest action is based on the counsel of the European Medicines Agency and member nations. .
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Roche Admits Long-Standing, Low-Level Contamination of Nelfinavir (July 26, 2007)
New information reveals contamination dating back to the drug's release in 1998; United States, Canada and Japan are the only unaffected countries.
From aidsmap.com - Viracept Recall Creates Panic in Zambia (June 19, 2007)
From United Nations Integrated Regional Information Networks - European Medicines Agency Recalls Roche Antiretroviral Viracept Because of Contamination (June 8, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - New Nelfinavir Formulation Now Available for Patients With HIV (June 1, 2004)
A Pfizer press release on nelfinavir's new twice-a-day dosing option.
From Pfizer, Inc. - Nelfinavir Available in 625 mg Formulation in United States (May 25, 2004)
The new dosing may allow Americans on the drug to switch from five to two doses daily.
From HIV InSite - Caution With Nelfinavir and Some Lipid-Lowering Drugs (November 21, 2001)
From Canadian AIDS Treatment Information Exchange
Clinical Management
Clinical Management
  |
  |